Outcome (n, %) | Survival (months) | p-value | HR (95% CI) | p-value |
---|---|---|---|---|
≥30% PSA response at 4 weeks (97) | ||||
Yes (38, 39.2) | 40.0 (23.9–55.0) | 0.014 | 0.54 (0.33–0.89) | 0.015 |
No (59, 60.8) | 19.7 (16.0–25.1) | |||
≥50% PSA response at 4 weeks (97) | ||||
Yes (32, 33.0) | 41.1 (23.2-NE) | 0.007 | 0.49 (0.28–0.83) | 0.006 |
No (65, 67.0) | 19.9 (16.0–26.1) | |||
≥30% PSA response at 8 weeks (95) | ||||
Yes (46, 48.4) | 40.0 (25.1–48.4) | 0.004 | 0.51 (0.32–0.82) | 0.005 |
No (49, 51.6) | 18.7 (16.0–23.9) | |||
≥50% PSA response at 8 weeks (95) | ||||
Yes (35, 36.8) | 37.4 (23.9–46.0) | 0.058 | 0.62 (0.38–1.02) | 0.054 |
No (60, 63.2) | 20.3 (17.8–26.1) | |||
≥30% PSA response at 12 weeks (93) | ||||
Yes (51, 54.8) | 35.2 (24.0–45.7) | 0.017 | 0.56 (0.35–0.91) | 0.019 |
No (42, 45.2) | 18.6 (13.4–23.9) | |||
≥50% PSA response at 12 weeks (93) | ||||
Yes (40, 43.0) | 40.0 (26.1–55.0) | 0.002 | 0.47 (0.29–0.77) | 0.002 |
No (54, 57.0) | 19.6 (15.0–23.9) |